Fast Locator 2011-2012: Cangene bioPharma - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Fast Locator 2011-2012: Cangene bioPharma



CANGENE bioPharma, is a contract manufacturer, providing fill/finish and support services for over 30 years. Located in Baltimore, MD, USA, close to the FDA, CANGENE bioPharma is highly compliant, having successfully passed inspections from numerous regulatory agencies in the US, EU, and Japan.

CANGENE bioPharma’s fill/finish services include:

  • Vial filling (3cc-100cc) - batches up to 85,000 5cc vials
  • Lyophilization (2 x 240 sq ft lyophilizers)
  • Syringe filling – 0.5cc–20cc syringes
  • Terminal Sterilization – with steam

CANGENE bioPharma prides itself on providing outstanding and flexible support to its partner companies. From clinical through commercial launch, CANGENE bioPharma has the experience, knowledgeable personnel and involved management team to ensure our partners’ products proceed from project initiation through manufacturing quickly with an emphasis on exceptional quality.

CANGENE bioPharma provides services to a worldwide customer base, including large, small and virtual pharmaceutical and biotechnology companies. CANGENE bioPharma produces products that are distributed in over 50 countries by our clients.


Regions covered:

North America


Outsourcing services provided:

Development and Phase I/II CTM

  • Injectable products development

Commercial Manufacturing

  • Injectables

Analytical Services

  • Chemistry and stability
  • Microbiology

Website:

www.cangenebiopharma.com

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes

Click here